LHLu Han

Lu Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lu Han has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Wang

    State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China

    1 shared publication
  • Di Wang

    Tissue Bank, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China

    1 shared publication
  • Haiyang Hu

    Central Laboratory, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China

    1 shared publication
  • Hu Zhou

    Department of Analytical Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

    1 shared publication
  • Huansha Yu

    Department of Animal Experimental Center, Innovation and Incubation Center, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China

    1 shared publication
  • Jijun Sun

    Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China

    1 shared publication

Latest Publications

  • Open Access

    Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy

    by Lele Zhang, Liangdong Sun, Shengnan Duan, Yilv Yan, Jinyi Song, Linghui Xia, Huansha Yu, Jijun Sun, Junjie Hu, Di Wang, et al.

    Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare yet highly aggressive subtype of non-small cell lung carcinoma (NSCLC) with limited therapeutic options. We conduct a comprehensive proteogenomic analysis of LCNEC using tumors and paired normal adjacent tissues from 107 patients (81 pure LCNEC and 26 combined LCNEC). APOBEC mutational signatures strongly correlate processes of tumor initiation and immune suppression, and KEAP1 mutations correlate with metabolic reprogramming in LCNEC combined with NSCLC. A conflicting relationship is observed between neuroendocrine and immune phenotypes. We identify three LCNEC subtypes with unique prognosis features, microenvironment dysregulation, genetic alterations, and potential therapeutic targets. Interleukin-33 (IL-33) emerges as a critical therapeutic biomarker associated with enhanced T cell infiltration and antitumor activity. We further optimize recombinant IL-33 (rIL33) with site-directed mutagenesis and develop PEGylated rIL33, demonstrating its prolonged circulation time in cynomolgus monkeys and superior immune agonist activity in mouse models. Overall, this study offers insights into LCNEC biology and provides promising innovative immunoagonist therapy strategies for lung cancer.